Breakthrough therapy designation 1 article

Breakthrough Therapy designation is an FDA program for drugs intended to treat serious or life-threatening conditions when preliminary clinical evidence indicates the potential for substantial improvement over available therapy on clinically significant endpoints. The designation can provide intensive guidance, organizational commitment and more frequent interaction with the agency. It is an expedited-development status, not marketing approval, and it does not by itself establish safety, efficacy or eventual regulatory success.